Chemotherapy‐induced neuropathy

  title={Chemotherapy‐induced neuropathy},
  author={Anthony J Windebank and Wolfgang Grisold},
  journal={Journal of the Peripheral Nervous System},
Abstract  Neurotoxic side effects of cancer therapy are second in frequency to hematological toxicity. Unlike hematological side effects that can be treated with hematopoietic growth factors, neuropathies cannot be treated and protective treatment strategies have not been effective. For the neurologist, the diagnosis of a toxic neuropathy is primarily based on the case history, the clinical and electrophysiological findings, and knowledge of the pattern of neuropathy associated with specific… 

Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Peripheral neuropathies induced by chemotherapy (CIPN) are an increasingly frequent problem, and concepts of rehabilitation need to be implemented to improve the patients' functions and quality of life.

Animal models of chemotherapy-evoked painful peripheral neuropathies

Chemotherapy-induced peripheral neuropathy.

  • J. Fehrenbacher
  • Biology, Psychology
    Progress in molecular biology and translational science
  • 2015

Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment

An evidence base for novel targets and both pharmacological and non-pharmacological treatments is beginning to emerge and has been recognised recently in publications by the American Society of Clinical Oncology and analgesic trial design expert groups such as ACTTION.

Chemotherapy-induced peripheral neurotoxicity

The mechanistic and clinical aspects of this unpredictable condition are considered, along with the controversial aspects of CIPN, including the onset mechanisms associated with the different drug types, assessment of the patient's condition, and the current status of neuroprotection and treatment options.

Prevention and Management of Platinum Compounds-Induced Neurotoxicity

This review highlights the etiology of platinum-drugs-induced neuropathy, and covers the preventative and therapeutic options for cancer patients, focusing on clinical studies conducted between 2010 and 2020.

Chemotherapy-induced peripheral neuropathy

The present review highlighted the current view of peripheral neuropathy during chemotherapeutic approaches by searching the electronic database PubMed for pre-clinically and clinically controlled trials reporting neuropathy of adverse effects, a result of chemotherapy in cancer patients.

Emerging Trends in Understanding Chemotherapy-Induced Peripheral Neuropathy

The aim of this review is to describe the clinical features of CIPN and to summarize the recent trends in understanding its pathophysiology.

Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review

These long-term effects are associated with comorbidities such as depression, insomnia, falls and decreases of health-related quality of life in cancer patients and survivors and it is noteworthy that these long- term effects remain poorly studied, and only limited data are available.



Management of chemotherapy-induced peripheral neuropathy

Basic and clinical researchers have begun to investigate therapy to prevent neurotoxic injury, and preliminary studies have shown promise for some agents including glutamine, glutathione, vitamin E, acetyl-L-carnitine, calcium, and magnesium infusions.

Neurological complications of cancer chemotherapy

Magnetic resonance diffusion-weighted and fluid-attenuated inversion-recovery imaging are useful in demonstrating chemotherapy-induced central nervous system lesions, which remain a major limitation of many drugs used in cancer patients.

The pathophysiology of oxaliplatin-induced neurotoxicity.

Recent developments in clinical rating scales and novel neurophysiological methods for the clinical investigation of chemotherapy-induced neurotoxicity will be focused on and it will be highlighted how such methods may prove useful to study the neurological effects of chemotherapy.

Peripheral neuropathy induced by microtubule-stabilizing agents.

  • James J. LeeS. Swain
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Although there have been several small clinical trials with neuroprotective agents, early recognition and supportive care are the best approaches for prevention and management of MTSA-induced neuropathy.

Oxaliplatin-safety profile: neurotoxicity.

  • A. Grothey
  • Biology, Medicine
    Seminars in oncology
  • 2003

Paclitaxel-induced neuropathy.

Using 3-weekly 3-hour infusions of paclitaxel, dose-limiting neurotoxicity can be expected in patients treated with 250 mg/m2 or more each cycle, and follow-up data of 12 patients after discontinuation of pac litaxel therapy showed that pac Litaxel-induced neuropathy is at least partially reversible.

Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil

Two patients treated in a phase I trial of oral 5-FU, leucovorin and eniluracil, an inhibitor of dihydropyrimidine dehydrogenase (DPD), developed delayed onset symptoms of unsteady gait and reduced sensation in the legs, and it is likely that5-FU or its active metabolites were contributing factors to the peripheral neuropathy.

Suramin-induced neuropathy in an animal model

Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients.

Hematopoietic toxicity of high-dose carboplatin chemotherapy can be tolerated by most of the patients, but careful monitoring of neuro- and, especially, ototoxicity should be planned.